Opko Health Inc.(NYSE:OPK) announced that the company will present new data on its long-acting clotting Factor VIIa-CTP (MOD-5014) at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress being held June 20-25, 2015 in Toronto, Ontario, Canada. OPKO’s Factor VIIa-CTP is a next-generation investigational therapy currently in a Phase 2a U.S. based study for the treatment of patients with hemophilia.
Currently, Factor VIIa therapy is available only as an intravenous (IV) formulation, which requires frequent multiple infusions to treat a bleeding episode due to Factor VIIa’s short half-life. In addition, the requirement for multiple weekly infusions can be onerous for patients interested in preventative prophylactic treatment of the disease, especially children.
Previously presented pre-clinical data utilizing both intravenous and subcutaneous administration in hemophilic animal models demonstrated the long acting properties of Factor VIIa-CTP as compared to commercial rFVIIa, with superior half-life, reduced bleeding and increased survival for a significantly longer period.
Five abstracts were accepted for presentation at the upcoming ISTH conference. The following abstracts will be presented from 5:00-7:00 p.m. local time on June 23-24th. (Original Source)
Shares of Opko Health opened today at $16.71 and are currently trading down at $16.04. OPK has a 1-year high of $19.20 and a 1-year low of $8.02. The stock’s 50-day moving average is $15.91 and its 200-day moving average is $13.06.
On the ratings front, Opko has been the subject of a number of recent research reports. In a report issued on May 12, Oppenheimer analyst Rohit Vanjani maintained a Hold rating on OPK. Separately, on March 26, Barrington Research’s Michael Petusky initiated coverage with a Buy rating on the stock and has a price target of $19.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Rohit Vanjani and Michael Petusky have a total average return of 39.2% and 10.3% respectively. Vanjani has a success rate of 82.1% and is ranked #14 out of 3614 analysts, while Petusky has a success rate of 68.8% and is ranked #1229.
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.